E
Estrella Immunopharma, Inc.
ESLAWCIK 0001844417NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthBiological Products, (No Diagnostic Substances)FY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-13.06M
Total Assets
—
Equity
—
Shares Out
43.03M
Op. Cash Flow
$-1.79M
Business
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company developing ARTEMIS® T‑cell therapies to address cancers and autoimmune diseases. Its main products include EB103 (CD19‑redirected ARTEMIS T‑cell therapy), EB104 (CD19/22 dual‑targeting ARTEMIS T‑cell therapy) and preclinical EB201, supported by Eureka’s ARTEMIS® platform and a collaboration with Imugene on CF33‑CD19t for a “mark and kill” solid tumor approach. The company operates clinical and preclinical development programs, maintains licensing and collaboration arrangements, and relies on clinical trial networks and partner collaborations across the United States, China and other international jurisdictions for development and potential commercialization.
Summary from filing dated 2024-09-27
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development (including $10,125,000 for the year ended December 31, 2025 and $2,801,435 for the six months ended December 31, 2024, from a related party) | 10 | 4 | 10 | — | — | |
| General and administrative | 3 | 3 | 663,190 | — | — | |
| Total operating expenses | 13 | 7 | 11 | — | — | |
| Loss from Operations | −13 | −7 | −11 | −2 | −249,146 | |
| Loss before income taxes | −13 | −7 | −11 | −915,456 | −247,718 | |
| Income tax provision | −838 | −1,625 | — | −80,648 | 0 | |
| Net loss | −13 | −7 | −11 | −996,104 | −247,718 | |
| Net loss applicable to common stock per share, basic (in Dollars per share) | −0.35 | −0.27 | −36.35 | — | — | |
| Net loss applicable to common stock per share, diluted (in Dollars per share) | −0.35 | −0.27 | −36.35 | — | — | |
| Weighted average common stock outstanding, basic (in Shares) | 37 | 27 | 305,748 | — | 1 | |
| Weighted average common stock outstanding, diluted (in Shares) | 37 | 27 | 305,748 | — | 1 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 1 | 916,916 | 4 | 2 | 40,802 | |
| Prepaid expenses and other receivable | 292,673 | 723,861 | 288,761 | — | — | |
| Total current assets | 2 | 2 | 4 | 3 | 52,427 | |
| Prepaid expenses, related party , non-current | 2 | 2 | — | — | — | |
| Total Assets | 3 | 3 | 4 | 3 | 10 | |
| Other payables and accrued liabilities | 238,414 | 201,760 | 131,823 | 398,781 | — | |
| Derivative liabilities | 356,505 | — | — | — | — | |
| Franchise tax payable | — | 4,134 | 4,134 | 4,297 | — | |
| Income tax payable | — | 50 | 40,744 | — | — | |
| Total current liabilities | 14 | 3 | 180,701 | 10 | 1 | |
| Total Liabilities | 14 | 3 | 180,701 | 10 | 3 | |
| Commitments and Contingencies (Note 4) | — | — | — | — | — | |
| Preferred Stock, $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2025 and 2024 | — | — | — | — | — | |
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 38,486,219 and 36,680,870 shares issued as of December 31, 2025 and 2024, respectively | 3,849 | 3,668 | 3,661 | 98 | 142 | |
| Additional paid-in capital | 27 | 25 | — | — | — | |
| Accumulated deficit | −37 | −24 | −20 | −12 | −2 | |
| Treasury stock, at cost 515,281 and 486,979 shares as of December 31, 2025 and 2024, respectively | −598,379 | −568,917 | −354,440 | — | — | |
| Total Stockholders (Deficit) Equity | −10 | 143,731 | 4 | −12 | −2 | |
| Total Liabilities and Stockholders (Deficit) Equity | 3 | 3 | 4 | 3 | 10 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 618,974 | 1 | 409,595 | — | — | |
| Change in fair value of derivative liabilities | 38,189 | — | — | — | — | |
| Prepaid expenses and other receivable | 431,188 | −149,994 | — | — | — | |
| Prepaid expenses - related party | — | — | 833,333 | — | — | |
| Accounts payable - related party | 550,346 | −9 | 8 | — | — | |
| Other payables and accrued liabilities | 36,654 | −449,958 | 122,594 | — | — | |
| Accrued liability - related party | 10 | −18,000 | 22,000 | — | — | |
| Franchise tax payable | −4,134 | — | — | — | — | |
| Income tax payables | −50 | −138 | 3,200 | 51,176 | — | |
| Net cash used in operating activities | −2 | −16 | −1 | −1 | −316,158 | |
| Payments of transactions cost | −117,473 | −2 | — | — | −579,974 | |
| Proceeds from issuance of common stock through stock purchase agreement | — | — | — | — | — | |
| Proceeds from issuance of common stock for PIPE investment | 2 | — | — | — | 25,000 | |
| Purchase of treasury stock | −29,462 | — | — | — | — | |
| Net cash provided by (used in) financing activities | 2 | 13 | — | −36 | 46 | |
| Net Change in Cash | 467,386 | 2 | −2 | — | — | |
| Cash paid for income tax | 913 | 1,600 | — | — | — | |
| Cash paid for interest | — | 2,663 | — | — | — | |
| Recognition of derivative liabilities upon closing of the PIPE investment | 318,316 | — | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro